Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Clinical Lung Cancer · 2024-12 · 25 (8) · 723-731.e2
DOI: 10.1016/j.cllc.2024.09.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2024-12. Verfasst von Diego Enrico und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina. Electronic address: denrico@alexanderfleming.org. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Pleural Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina. Electronic address: denrico@alexanderfleming.org.
- Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
- Department of Medical Oncology, Upper Gastrointestinal and Endocrine Tumor Group, Vall´d Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Clinical Oncology Unit, Hospital Universitario Austral, Pilar Buenos Aires, Argentina; Laboratorio de Inmuno-biología del Cáncer, Instituto de Investigaciones en Medicina Traslacional, Universidad Austral-Consejo Nacion…
- Clinical Oncology Unit, Hospital Universitario Austral, Pilar Buenos Aires, Argentina.
- Departamento de Oncología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Zitieren
APA
Enrico, D., Gomez, J. E., Aguirre, D., Tissera, N. S., Tsou, F., Pupareli, C., Tanco, D. P., Waisberg, F., Rodríguez, A., Rizzo, M., Minatta, N., Rafael, P., Basbus, L., Lupinacci, L., Kaen, D., Ramos, M., Bluthgen, V., Castagneris, N., Coppola, M. P., …, & Martín, C. (2024). Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM). Clinical Lung Cancer, 25(8), 723-731.e2. https://doi.org/10.1016/j.cllc.2024.09.005
Vancouver
Enrico D, Gomez JE, Aguirre D, Tissera NS, Tsou F, Pupareli C, et al. Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM). Clinical Lung Cancer. 2024;25(8):723-731.e2. doi:10.1016/j.cllc.2024.09.005
BibTeX
@article{Enrico2024,
author = {Enrico, Diego and Gomez, Juan Elias and Aguirre, Danilo and Tissera, Natalia Soledad and Tsou, Florencia and Pupareli, Carmen and Tanco, Delfina Peralta and Waisberg, Federico and Rodríguez, Andrés and Rizzo, Manglio and Minatta, Nicolás and Rafael, Picon and Basbus, Luis and Lupinacci, Lorena and Kaen, Diego and Ramos, Mauro and Bluthgen, Virginia and Castagneris, Nicolas and Coppola, María Pía and Scocimarro, Alejandra and Guerra, María Florencia and Perfetti, Aldo and Levit, Patricio and Galvez-Nino, Marco and Mas, Luis and Rojas, Leonardo and Zuluaga, Jairo and Chacón, Matías and Corrales, Luis and Samtani, Suraj and Arrieta, Oscar and Cardona, Andrés and Remon, Jordi and Martín, Claudio},
title = {Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
number = {8},
pages = {723--731.e2},
doi = {10.1016/j.cllc.2024.09.005}
}
EUVIMED